This video is the first in a series on vaccines, focusing on the AstraZeneca vaccine specifically. The host explains that the vaccine is a result of a partnership between AstraZeneca and the University of Oxford. It is made using viral vector technology, taking a chimpanzee cold virus that doesn't cause disease in humans, and modifying it to carry a genetic fragment of the coronavirus. This stimulates the immune system to produce a response against the coronavirus.
The vaccine is administered in a two-dose regimen, with the first dose given 12 weeks before the second. This long interval ensures greater protection. The vaccine has an effectiveness of around 70% at 11 days after the first dose, and more than 80% after the second dose. Real-life vaccine performance data shows that the AstraZeneca vaccine reduced the risk of hospitalization by 88% one month after the first dose.
The vaccine is effective for almost all variants of the virus circulating today, with the exception of the Beta variant identified in South Africa. However, this variant is not widespread in Brazil, so the AstraZeneca vaccine is still recommended. The Delta variant, first identified in India, also poses concerns, but the vaccine continues to be effective against it, especially after the second dose.
The host emphasizes the importance of taking both doses and encourages viewers to go to the health center to receive the second dose on the scheduled date. Despite the technology used in the vaccine generating more reactions than traditional vaccines, the most common adverse reactions are at the injection site, such as sensitivity, pain, itching, swelling, and hardening at the site. These reactions are typically mild to moderate in intensity and disappear within three days after vaccination. The host concludes by reminding viewers to maintain protective measures even after vaccination.
Here are the key facts extracted from the text:
1. The AstraZeneca vaccine was developed in partnership between AstraZeneca and the University of Oxford in the United Kingdom.
2. The vaccine is also known as the Oxford vaccine.
3. The AstraZeneca vaccine uses viral vector technology.
4. The vaccine works by using a modified chimpanzee cold virus to carry a genetic fragment of the coronavirus.
5. The vaccine stimulates the immune system to produce a response against the coronavirus.
6. The vaccine was tested and approved with a two-dose regimen.
7. The interval between the first and second dose is 12 weeks in Brazil.
8. The AstraZeneca vaccine has an effectiveness of around 70% 11 days after the first dose.
9. The vaccine's effectiveness can reach over 80% after the second dose.
10. The vaccine reduces the person's risk of hospitalization by 88% one month after the first dose.
11. The vaccine may prevent the vaccinated person from transmitting the virus if they become infected, but more research is needed to confirm this.
12. The AstraZeneca vaccine is effective against most variants of the coronavirus, but it has a reduced effectiveness against the Beta variant.
13. The vaccine has a lower effectiveness against the Delta variant, but it still provides protection, especially after the second dose.
14. The most common side effects of the vaccine are reactions at the injection site, such as sensitivity, pain, itching, swelling, and hardening.
15. General disorders such as headache, fatigue, malaise, fever, chills, tremors, nausea, and muscle pain can also occur.
16. Other symptoms such as dizziness, drowsiness, and abdominal pain can occur, but are less common.
17. Most side effects are mild to moderate in intensity and disappear within three days after vaccination.
18. The reactions observed after the second dose are milder and less frequent compared to the first dose.
19. There have been rare cases of thrombosis associated with a low platelet count after taking the vaccine.
20. The risk of thrombosis is estimated to be around 1 in 100,200,000 vaccinated people.
21. People who have a risk factor for the development of thrombosis do not have a higher risk of having post-vaccine thrombosis.
22. The vaccine is contraindicated for people who have a hypersensitivity or allergy to any of the components of the vaccine.
23. The vaccine is also contraindicated for people who have had thrombosis associated with a low platelet count after taking a vaccine.
24. The vaccine should not be administered to people who are sick and have a high fever.
25. There are limited data on the use of the AstraZeneca vaccine in pregnant and lactating women, and it is not recommended for these groups as a precautionary measure.